Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 8.28% is 194% above its 5-year average of 2.81%, near the high end of its 5-year range (0.00%–8.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 86.36% above its 12-month average of 4.44%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.28%.
DEBT TO ASSETS RATIO
8.28%
DEBT TO ASSETS RATIO AVG TTM
4.44%
DEBT TO ASSETS RATIO AVG 3Y
2.73%
DEBT TO ASSETS RATIO AVG 5Y
2.81%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+86.36%
CURRENT VS 3Y AVG
+203.18%
CURRENT VS 5Y AVG
+194.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 580 covered companies
CURRENT VS SECTOR MEDIAN
+8179.74%
vs the sector median at left
Disc Medicine, Inc.
Market Cap
$2.40B
Debt to Assets Ratio
8.28%
TTM Avg
4.44%
3Y Avg
2.73%
5Y Avg
2.81%
Market Cap
$2.42B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.42B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.47B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.30B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.56B
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.40B | 8.28% | 4.44% | 2.73% | 2.81% |
| Liquidia Corporation (LQDA)vs › | $2.42B | 0.25% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | 0.05% | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | 0.00% | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.47B | 0.13% | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.32B | 0.30% | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | 0.29% | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.56B | 0.18% | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 0.11% | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | 0.00% | N/A | N/A | N/A |
Debt/Assets
8.3%
Debt/Equity
0.09
Current Ratio
24.14
Interest Coverage
-65.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 8.28% |
| 2026-03-31 | 4.14% |
| 2025-12-31 | 0.23% |
| 2025-09-30 | 4.91% |
| 2025-06-30 | 4.65% |
| 2025-03-31 | 4.32% |
| 2024-12-31 | 6.04% |
| 2024-09-30 | 0.36% |
| 2024-06-30 | 0.36% |
| 2024-03-31 | 0.57% |
| 2023-12-31 | 0.57% |
| 2023-09-30 | 0.52% |
| 2023-06-30 | 0.54% |
| 2023-03-31 | 0.52% |
| 2022-12-31 | 0.67% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 2.57% |
| 2022-03-31 | 3.35% |
| 2021-12-31 | 7.64% |
| 2021-09-30 | 4.27% |
| 2021-06-30 | 4.58% |
| 2021-03-31 | 4.82% |
| 2020-12-31 | 260.13% |
